Healthcare Industry News: Celsion
News Release - January 19, 2006
Celsion Adds Staff to Drug Development TeamCelsion appoints Dr. William Hahne as Vice President Clinical Development and Medical Affairs and Dr. Christopher Black as Executive Director, Preclinical Research
COLUMBIA, Md.--(HSMN NewsFeed)--Jan. 19, 2006--Celsion CORPORATION (AMEX:CLN ) today announced that it had appointed William Hahne M.D., as Vice President Clinical Development and Medical Affairs and Christopher Black, Ph.D. as Executive Director, Preclinical Research.
Dr. Hahne has extensive experience in the management of clinical trial programs including oncology drug trial design and implementation. In his most recent position as Vice President, Clinical Development at Curagen Corporation, Dr. Hahne managed all clinical aspects of the company's oncology drug development program. Prior to Curagen from 1986 to 2002, he served in increasingly senior positions at Glaxo Inc., Hoechst Marion Roussel and Eisai Inc., Dr. Hahne earned his M.D. at Cornell University Medical School.
Dr. Black who was a John E. Fogarty Fellow and Associate at the National Institutes of Health and a lecturer at Harvard Medical School earned his Ph.D. at the University of London in the United Kingdom and has led preclinical development groups at companies such as Protarga, Nycomed Amersham and Sterling Winthrop Imaging. He has extensive experience in the development of anticancer therapeutics and diagnostics, as well as the development of liposomal based drug carrier systems.
Dr. Lawrence Olanoff, Celsion's Chief Executive Officer, commented, "I am delighted that Bill and Chris have joined our team. Their research and development experience will be invaluable as we continue to build a portfolio of oncology products. Drs. Hahne and Black have extensive oncology experience which will contribute substantially to our progress as we focus entirely on oncology drug development. We remain committed to building a portfolio of oncology applications by using our heat activated drug delivery technology as a platform and thus create greater shareholder value."
ABOUT Celsion: Celsion Corporation, based in Columbia, Maryland, is a biotechnology company dedicated to the development and commercialization of heat activated treatment systems for cancer.
Celsion has research, license or commercialization agreements with leading institutions such as the National Institute of Health, Duke University Medical Center, Massachusetts Institute of Technology, Harbor UCLA Medical Center, Montefiore Medical Center and Memorial Sloan-Kettering Cancer Center in New York City, Roswell Park Cancer Institute in Buffalo, New York, and Duke University. For more information on Celsion, visit our website: www.Celsion.com.
Celsion wishes to inform readers that forward-looking statements in this release are made pursuant to the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. Readers are cautioned that such forward-looking statements involve risks and uncertainties including, without limitation, unforeseen changes in the course of research and development activities and in clinical trials by others; possible acquisitions of other technologies, assets or businesses; possible actions by customers, suppliers, competitors, regulatory authorities; and other risks detailed from time to time in the Company's periodic reports filed with the Securities and Exchange Commission. In addition, Celsion's receipt of the royalty payments in connection with the sale of Celsion (Canada) depends upon the ability of Celsion (Canada) to develop the APA technology and bring products to market. This involves, among other risks of a new enterprise, financing, regulatory and market acceptance risks.
Issuer of this News Release is solely responsible for its
Please address inquiries directly to the issuing company.